Details of the Drug

General Information of Drug (ID: DMPQAGE)

Drug Name
Mycophenolate mofetil
Synonyms
mycophenolate mofetil; 128794-94-5; CellCept; 115007-34-6; RS 61443; RS-61443; Munoloc; Mycophenolic acid morpholinoethyl ester; TM-MMF; Mycophenylate mofetil; Mycophenolatemofetil; UNII-9242ECW6R0; HSDB 7436; Cellcept (TN); 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; CHEBI:8764; C23H31NO7; Mycophenolate mofetil (CellCept); 9242ECW6R0; 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate; Myfenax; RS-61443-190; CellCept; MMF; CellCept (TN); ME-MPA; MMF CellCept(TM); R-99; Mycophenolate mofetil (JAN/USAN); CellCept, RS 61443, TM-MMF, Mycophenolate mofetil; 2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate; 2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate; 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate;4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
Indication
Disease Entry ICD 11 Status REF
Organ transplant rejection NE84 Approved [1], [2]
Pemphigus vulgaris EB40 Phase 3 [1], [2]
Immune System disease 4A01-4B41 Investigative [3]
Therapeutic Class
Immunosuppressive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 433.5
Topological Polar Surface Area (xlogp) 3.2
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Elimination
0% of drug is excreted from urine in the unchanged form [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 47.4536 micromolar/kg/day [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.043 mg/mL [4]
Chemical Identifiers
Formula
C23H31NO7
IUPAC Name
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
Canonical SMILES
CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\\C)/CCC(=O)OCCN3CCOCC3)O
InChI
InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+
InChIKey
RTGDFNSFWBGLEC-SYZQJQIISA-N
Cross-matching ID
PubChem CID
5281078
ChEBI ID
CHEBI:8764
CAS Number
128794-94-5
DrugBank ID
DB00688
TTD ID
D04FBR
VARIDT ID
DR00243
INTEDE ID
DR1118
ACDINA ID
D00449

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) TTTB4UP IMDH2_HUMAN Inhibitor [6]
Prostaglandin E2 receptor EP2 (PTGER2) TT1ZAVI PE2R2_HUMAN Modulator [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [7]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [8]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [7]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [7]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [9]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [9]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [9]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [9]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [11]
UDP-glucuronosyltransferase 1A10 (UGT1A10) DEL5N6Y UD110_HUMAN Substrate [12]
UDP-glucuronosyltransferase 1A6 (UGT1A6) DESD26P UD16_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Organ transplant rejection
ICD Disease Classification NE84
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin E2 receptor EP2 (PTGER2) DTT PTGER2 2.77E-06 1.15 1.37
P-glycoprotein 1 (ABCB1) DTP P-GP 9.96E-01 9.10E-02 1.78E-01
Breast cancer resistance protein (ABCG2) DTP BCRP 3.20E-01 -2.44E-01 -2.70E-01
Multidrug resistance-associated protein 2 (ABCC2) DTP MRP2 6.57E-01 -7.03E-03 -3.29E-02
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 7.75E-01 3.79E-03 1.43E-02
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 5.94E-01 -5.43E-03 -2.82E-02
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.98E-01 1.01E-01 3.33E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 7.97E-02 -4.55E-02 -3.54E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 3.74E-03 -6.47E-02 -1.18E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 9.50E-01 8.27E-02 3.14E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Mycophenolate mofetil
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Azathioprine DMMZSXQ Moderate Additive myelosuppressive effects by the combination of Mycophenolate mofetil and Azathioprine. Transplant rejection [NE84] [130]
Coadministration of a Drug Treating the Disease Different from Mycophenolate mofetil (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Moderate Decreased absorption of Mycophenolate mofetil due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [131]
Clindamycin DM15HL8 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Clindamycin. Acne vulgaris [ED80] [130]
Cefuroxime DMSIMD8 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefuroxime. Acute bronchitis [CA42] [130]
Framycetin DMF8DNE Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Framycetin. Alcoholic liver disease [DB94] [130]
Paromomycin DM1AGXN Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Paromomycin. Amoebiasis [1A36] [130]
Metronidazole DMTIVEN Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Metronidazole. Amoebiasis [1A36] [130]
Cefamandole DMNEXZF Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefamandole. Anaerobic bacterial infection [1A00-1A09] [130]
Aminophylline DML2NIB Minor Increased plasma concentration of Mycophenolate mofetil and Aminophylline due to competitive binding of plasma proteins. Asthma [CA23] [130]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Roflumilast. Asthma [CA23] [132]
Cefotetan DM07TX3 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefotetan. Bacterial infection [1A00-1C4Z] [130]
Ofloxacin DM0VQN3 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [130]
Kanamycin DM2DMPO Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Kanamycin. Bacterial infection [1A00-1C4Z] [130]
Tindamax DM3OWT4 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Tindamax. Bacterial infection [1A00-1C4Z] [130]
Ceftizoxime DM3VOGS Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Ceftizoxime. Bacterial infection [1A00-1C4Z] [130]
Dalfopristin DM4LTKV Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Dalfopristin. Bacterial infection [1A00-1C4Z] [130]
Clarithromycin DM4M1SG Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Clarithromycin. Bacterial infection [1A00-1C4Z] [130]
Ticarcillin DM4ME02 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Ticarcillin. Bacterial infection [1A00-1C4Z] [130]
Cefoperazone DM53PV8 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefoperazone. Bacterial infection [1A00-1C4Z] [130]
Meropenem DM62UHC Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Meropenem. Bacterial infection [1A00-1C4Z] [130]
Cefprozil DM7DSYP Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefprozil. Bacterial infection [1A00-1C4Z] [130]
Sulfamethoxazole DMB08GE Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [130]
Sparfloxacin DMB4HCT Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [130]
Ceftriaxone DMCEW64 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Ceftriaxone. Bacterial infection [1A00-1C4Z] [130]
Streptomycin DME1LQN Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Streptomycin. Bacterial infection [1A00-1C4Z] [130]
Dalbavancin DMGMNH3 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Dalbavancin. Bacterial infection [1A00-1C4Z] [130]
Gemifloxacin DMHT34O Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [130]
Cefepime DMHVWIK Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefepime. Bacterial infection [1A00-1C4Z] [130]
Imipenem DMI9FBP Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Imipenem. Bacterial infection [1A00-1C4Z] [130]
Meticillin DMIKHN0 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Meticillin. Bacterial infection [1A00-1C4Z] [130]
Norfloxacin DMIZ6W2 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [130]
ABT-492 DMJFD2I Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by ABT-492. Bacterial infection [1A00-1C4Z] [130]
Cefpodoxime DMJUNY5 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefpodoxime. Bacterial infection [1A00-1C4Z] [130]
Cefaclor DMJXDGC Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefaclor. Bacterial infection [1A00-1C4Z] [130]
Gentamicin DMKINJO Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Gentamicin. Bacterial infection [1A00-1C4Z] [130]
Cefadroxil DMMC345 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefadroxil. Bacterial infection [1A00-1C4Z] [130]
Rabeprazole DMMZXIW Moderate Decreased absorption of Mycophenolate mofetil due to altered gastric pH caused by Rabeprazole. Bacterial infection [1A00-1C4Z] [130]
Bacampicillin DMP54C7 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Bacampicillin. Bacterial infection [1A00-1C4Z] [130]
Cefazolin DMPDYFR Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefazolin. Bacterial infection [1A00-1C4Z] [130]
Netilmicin DMRD1QK Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Netilmicin. Bacterial infection [1A00-1C4Z] [130]
Novobiocin DMRFWGK Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Novobiocin. Bacterial infection [1A00-1C4Z] [130]
Levofloxacin DMS60RB Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [130]
Cefditoren DMSUVM1 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefditoren. Bacterial infection [1A00-1C4Z] [130]
Oxacillin DMTAFY4 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Oxacillin. Bacterial infection [1A00-1C4Z] [130]
Cefonicid DMTX2BH Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefonicid. Bacterial infection [1A00-1C4Z] [130]
Cefradine DMUNSWV Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefradine. Bacterial infection [1A00-1C4Z] [130]
Cloxacillin DMUTL7O Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cloxacillin. Bacterial infection [1A00-1C4Z] [130]
Amoxicillin DMUYNEI Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Amoxicillin. Bacterial infection [1A00-1C4Z] [130]
Troleandomycin DMUZNIG Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Troleandomycin. Bacterial infection [1A00-1C4Z] [130]
Minocycline DMVN5OH Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Minocycline. Bacterial infection [1A00-1C4Z] [130]
Lomefloxacin DMVRH9C Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [130]
Cefoxitin DMYTXVR Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cefoxitin. Bacterial infection [1A00-1C4Z] [130]
Tetracycline DMZA017 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Tetracycline. Bacterial infection [1A00-1C4Z] [130]
Ceftibuten DMWV2AG Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Ceftibuten. Bronchitis [CA20] [130]
Oxtriphylline DMLHSE3 Minor Increased plasma concentration of Mycophenolate mofetil and Oxtriphylline due to competitive binding of plasma proteins. Cough [MD12] [130]
SODIUM CITRATE DMHPD2Y Moderate Decreased absorption of Mycophenolate mofetil due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [131]
Benzylpenicillin DMS9503 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Benzylpenicillin. Discovery agent [N.A.] [130]
Fosphenytoin DMOX3LB Minor Increased plasma concentration of Mycophenolate mofetil and Fosphenytoin due to competitive binding of plasma proteins. Epilepsy/seizure [8A61-8A6Z] [130]
Ethotoin DMXWOCP Minor Increased plasma concentration of Mycophenolate mofetil and Ethotoin due to competitive binding of plasma proteins. Epilepsy/seizure [8A61-8A6Z] [130]
Lincomycin DMVTHER Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Lincomycin. Gram-positive bacterial infection [1B74-1F40] [130]
Rifampin DMA8J1G Major Decreased clearance of Mycophenolate mofetil and Rifampin due to competitive inhibition of the same transporter. HIV-infected patients with tuberculosis [1B10-1B14] [132]
Didanosine DMI2QPE Moderate Decreased absorption of Mycophenolate mofetil due to altered gastric pH caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [131]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Mycophenolate mofetil and Teriflunomide. Hyper-lipoproteinaemia [5C80] [133]
Quinapril DMR8H31 Moderate Decreased absorption of Mycophenolate mofetil due to formation of complexes caused by Quinapril. Hypertension [BA00-BA04] [132]
TP-434 DM5A31S Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by TP-434. Infectious gastroenteritis/colitis [1A40] [130]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Mycophenolate mofetil and Denosumab. Low bone mass disorder [FB83] [134]
Sulphadoxine DMZI2UF Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Sulphadoxine. Malaria [1F40-1F45] [130]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Mycophenolate mofetil due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [135]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Tecfidera. Multiple sclerosis [8A40] [136]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Siponimod. Multiple sclerosis [8A40] [137]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Fingolimod. Multiple sclerosis [8A40] [138]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Ocrelizumab. Multiple sclerosis [8A40] [139]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Ozanimod. Multiple sclerosis [8A40] [132]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [140]
Esomeprazole DM7BN0X Moderate Decreased absorption of Mycophenolate mofetil due to altered gastric pH caused by Esomeprazole. Peptic ulcer [DA61] [130]
Gatifloxacin DMSL679 Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [130]
Colistimethate DMZ9BMU Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Colistimethate. Respiratory infection [CA07-CA4Z] [130]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Rilonacept. Rheumatoid arthritis [FA20] [141]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Golimumab. Rheumatoid arthritis [FA20] [142]
Sulfasalazine DMICA9H Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Sulfasalazine. Rheumatoid arthritis [FA20] [130]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Mycophenolate mofetil and Leflunomide. Rheumatoid arthritis [FA20] [133]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Mycophenolate mofetil when combined with Anthrax vaccine. Sepsis [1G40-1G41] [143]
Cephapirin DMV2JNY Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cephapirin. Sepsis [1G40-1G41] [130]
Tedizolid DMG2SKR Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Tedizolid. Skin and skin-structure infection [1F28-1G0Z] [130]
Pitolisant DM8RFNJ Moderate Accelerated clearance of Mycophenolate mofetil due to the transporter induction by Pitolisant. Somnolence [MG42] [132]
Cinoxacin DM4EWNS Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Cinoxacin. Urinary tract infection [GC08] [130]
Nitrofurantoin DM7PQIK Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Nitrofurantoin. Urinary tract infection [GC08] [130]
Doripenem DM9UCJK Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Doripenem. Urinary tract infection [GC08] [130]
Plazomicin DMKMBES Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Plazomicin. Urinary tract infection [GC08] [130]
Nalidixic acid DMRM0JV Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Nalidixic acid. Urinary tract infection [GC08] [130]
Mezlocillin DMY5JEP Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Mezlocillin. Urinary tract infection [GC08] [130]
Secnidazole DMJ18YL Moderate Altered absorption of Mycophenolate mofetil due to GI flora changes caused by Secnidazole. Vaginal discharge [MF3A] [130]
⏷ Show the Full List of 91 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
⏷ Show the Full List of 29 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Mycophenolate mofetil 250 mg capsule 250 mg Oral Capsule Oral
Mycophenolate mofetil 500 mg tablet 500 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6831).
2 Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
4 BDDCS applied to over 900 drugs
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Clinical pipeline report, company report or official report of Roche (2009).
7 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
8 Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64.
9 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
10 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
11 The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
12 [Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. 2001;22(7):331-7.
13 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
23 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
24 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
25 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
26 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
27 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
28 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
29 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
30 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
31 Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007 Aug;35(8):1315-24.
32 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
33 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
34 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
35 Drug Interactions Flockhart Table
36 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
37 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
38 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
39 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
40 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
41 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
42 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
43 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
44 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
45 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
46 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
47 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
48 Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87.
49 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
50 Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
51 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
52 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
53 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
54 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
55 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
56 Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
57 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
58 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
59 The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
60 S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
61 UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables. Drug Metab Dispos. 2011 Sep;39(9):1650-7.
62 UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6.
63 Pharmacokinetics of propofol and extrahepatic UGT1A6 gene expression in anhepatic rats. Pharmacology. 2009;84(4):219-26.
64 Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6.
65 Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants. Drug Metab Dispos. 2009 Feb;37(2):322-9.
66 Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev. 1999 Nov;31(4):817-99.
67 Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics. 2004 Aug;14(8):487-99.
68 Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem. 2007 Dec 14;282(50):36514-24.
69 Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
70 Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo. Cancer Prev Res (Phila). 2013 Jul;6(7):719-30.
71 In vitro metabolism, permeability, and efflux of bazedoxifene in humans. Drug Metab Dispos. 2010 Sep;38(9):1471-9.
72 UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 2005 Apr;106(1):97-132.
73 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
74 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
75 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
76 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
77 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
78 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
79 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
80 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
81 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
82 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
83 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
84 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
85 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
86 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
87 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
88 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
89 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
90 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
91 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
92 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
93 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
94 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
95 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
96 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
97 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
98 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
99 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
100 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
101 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
102 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
103 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
104 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
105 FDA Drug Development and Drug Interactions
106 Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
107 LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
108 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
109 Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
110 Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
111 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
112 Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46.
113 Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
114 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
115 Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience. 2007 May 25;146(3):1117-27.
116 Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
117 Clinical pipeline report, company report or official report of Santen Pharmaceutical.
118 Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
119 Pfizer. Product Development Pipeline. March 31 2009.
120 A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809-17.
121 Clinical pipeline report, company report or official report of Tempest Therapeutics.
122 Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
123 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
124 Structure-activity relationships for inhibition of inosine monophosphate dehydrogenase and differentiation induction of K562 cells among the mycoph... Bioorg Med Chem. 2010 Nov 15;18(22):8106-11.
125 Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment. J Med Chem. 2007 Dec 27;50(26):6685-91.
126 Bis(sulfonamide) isosters of mycophenolic adenine dinucleotide analogues: inhibition of inosine monophosphate dehydrogenase. Bioorg Med Chem. 2008 Aug 1;16(15):7462-9.
127 Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8.
128 Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett. 2006 May 1;16(9):2539-42.
129 Novel mycophenolic adenine bis(phosphonate) analogues as potential differentiation agents against human leukemia. J Med Chem. 2002 Jan 31;45(3):703-12.
130 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
131 Bullingham R, Shah J, Goldblum R, Schiff M "Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients." Br J Clin Pharmacol 41 (1996): 513-6. [PMID: 8799515]
132 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
133 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
134 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
135 Canadian Pharmacists Association.
136 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
137 Cerner Multum, Inc. "Australian Product Information.".
138 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
139 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
140 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
141 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
142 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
143 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]